Obama Cools the Stem-Cell Debate
By Jesse Reynolds,
San Francisco Chronicle
| 04. 27. 2009
While juggling a collapsing economy and major initiatives during his first months in office, President Obama tackled - and cooled - a contentious issue that has simmered for almost 10 years: embryonic stem cell research. His March 9 executive order fulfilled a campaign promise to lift his predecessor's restrictions on its federal funding.
The president outlined his new approach, leaving the details up to the National Institutes of Health. A week ago, the NIH unveiled its draft guidelines.
The new regulations would permit federal support for research with stem cell lines derived from embryos that are created, but not used, for fertility treatments. There are hundreds of thousands of such excess embryos in storage, most scheduled for eventual destruction regardless of scientists' activities. At the same time, federal support would not be permitted for work with stem cell lines derived from embryos created with cloning techniques - if any are ever successfully produced.
This is a thoughtful approach, and the right thing to do.
There are very good reasons - technical, ethical and political - why cloning-based stem cell research...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...